CA2577284A1 - Prostaglandin derivatives for treating gastrointestinal disorder - Google Patents

Prostaglandin derivatives for treating gastrointestinal disorder Download PDF

Info

Publication number
CA2577284A1
CA2577284A1 CA002577284A CA2577284A CA2577284A1 CA 2577284 A1 CA2577284 A1 CA 2577284A1 CA 002577284 A CA002577284 A CA 002577284A CA 2577284 A CA2577284 A CA 2577284A CA 2577284 A1 CA2577284 A1 CA 2577284A1
Authority
CA
Canada
Prior art keywords
composition
halogen
administered
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002577284A
Other languages
English (en)
French (fr)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2577284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2577284A1 publication Critical patent/CA2577284A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002577284A 2004-09-02 2005-09-01 Prostaglandin derivatives for treating gastrointestinal disorder Withdrawn CA2577284A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US60/606,521 2004-09-02
US66631705P 2005-03-30 2005-03-30
US60/666,317 2005-03-30
US66659305P 2005-03-31 2005-03-31
US60/666,593 2005-03-31
PCT/JP2005/016464 WO2006025599A1 (en) 2004-09-02 2005-09-01 Prostaglandin derivatives for treating gastrointestinal disorder

Publications (1)

Publication Number Publication Date
CA2577284A1 true CA2577284A1 (en) 2006-03-09

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002577284A Withdrawn CA2577284A1 (en) 2004-09-02 2005-09-01 Prostaglandin derivatives for treating gastrointestinal disorder

Country Status (16)

Country Link
US (2) US8748481B2 (https=)
EP (1) EP1791545B1 (https=)
JP (4) JP2008511541A (https=)
KR (4) KR20180033310A (https=)
CN (1) CN102885821A (https=)
AR (1) AR050626A1 (https=)
AU (1) AU2005278323B2 (https=)
BR (1) BRPI0514891A (https=)
CA (1) CA2577284A1 (https=)
ES (1) ES2603381T3 (https=)
IL (1) IL181332A (https=)
MX (1) MX2007002602A (https=)
NO (1) NO340989B1 (https=)
NZ (1) NZ553434A (https=)
TW (1) TWI387454B (https=)
WO (1) WO2006025599A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562604T3 (da) * 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
EP1984027B1 (en) * 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP2015514681A (ja) * 2012-04-23 2015-05-21 スキャンポ・アーゲーSucampo AG 下痢を伴う過敏性腸症候群の処置方法
MY176162A (en) * 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
RU2695274C3 (ru) 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2002094274A1 (en) 2001-05-18 2002-11-28 Sucampo Ag Cathartic composition
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
ATE489096T1 (de) 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Also Published As

Publication number Publication date
JP6408426B2 (ja) 2018-10-17
TWI387454B (zh) 2013-03-01
AR050626A1 (es) 2006-11-08
ES2603381T3 (es) 2017-02-27
EP1791545A1 (en) 2007-06-06
KR20170003712A (ko) 2017-01-09
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
EP1791545B1 (en) 2016-08-31
NO20071704L (no) 2007-05-31
US8748481B2 (en) 2014-06-10
NZ553434A (en) 2010-01-29
JP2018150354A (ja) 2018-09-27
WO2006025599A1 (en) 2006-03-09
KR20140019006A (ko) 2014-02-13
AU2005278323B2 (en) 2011-03-17
JP2015166377A (ja) 2015-09-24
BRPI0514891A (pt) 2008-06-24
JP2013049688A (ja) 2013-03-14
JP2008511541A (ja) 2008-04-17
US20140315994A1 (en) 2014-10-23
KR20180033310A (ko) 2018-04-02
IL181332A (en) 2015-09-24
MX2007002602A (es) 2007-04-25
CN102885821A (zh) 2013-01-23
TW200612901A (en) 2006-05-01
AU2005278323A1 (en) 2006-03-09
NO340989B1 (no) 2017-07-31
IL181332A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
US20130143958A1 (en) Dosage unit comprising a prostaglandin analog for treating constipation
US20140315994A1 (en) Method for treating gastrointestinal disorder
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
US10561649B2 (en) Pharmaceutical combination of opioid and prostaglandin compound
RU2392941C2 (ru) Производные простагландинов для лечения желудочно-кишечного нарушения
US20130281526A1 (en) Method for treating irritable bowel syndrome with diarrhea

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application

Effective date: 20210408